aTYR PHARMA (ATYR) Other Non-Current Assets (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Other Non-Current Assets came in at $1.8 million in Q1 2026, down 25.78% YoY from $2.4 million in Q1 2025, and down 19.24% on a QoQ basis from $2.2 million in Q4 2025.
aTYR PHARMA (ATYR) Other Non-Current Assets (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Other Non-Current Assets data on file, last reported at $1.8 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 25.78% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 25.78% YoY) and the FY2025 annual result came in at $2.2 million, down 24.26% from the prior year.
- Other Non-Current Assets retreated to $1.8 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $3.5 million in Q4 2023 to a low of $66000.0 in Q2 2025.
- A 5-year average of $2.4 million and a median of $2.9 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 1317.09% — and 2025, when it plunged 97.72%.
- Tracing ATYR's Other Non-Current Assets over 5 years: stood at $3.2 million in 2022, then grew by 10.08% to $3.5 million in 2023, then declined by 15.3% to $3.0 million in 2024, then slipped by 24.26% to $2.2 million in 2025, then fell by 19.24% to $1.8 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.8 million (Q1 2026), $2.2 million (Q4 2025), and $149000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Mn |
| Mar 31, 2026 | 1.81 Mn |
| Dec 31, 2025 | 2.24 Mn |
| Sep 30, 2025 | 149,000.00 |
| Jun 30, 2025 | 66,000.00 |
| Mar 31, 2025 | 2.43 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Sep 30, 2024 | 2.93 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Mar 31, 2024 | 3.21 Mn |
| Dec 31, 2023 | 3.48 Mn |
| Sep 30, 2023 | 3.45 Mn |
| Jun 30, 2023 | 3.42 Mn |
| Mar 31, 2023 | 3.19 Mn |
| Dec 31, 2022 | 3.17 Mn |
| Sep 30, 2022 | 2.24 Mn |
| Jun 30, 2022 | 733,000.00 |
| Sep 30, 2021 | 158,000.00 |
| Jun 30, 2021 | 152,000.00 |
| Mar 31, 2021 | 234,000.00 |